NasdaqCM - Nasdaq Real Time Price USD
Forte Biosciences, Inc. (FBRX)
11.32
+0.97
+(9.37%)
At close: June 6 at 4:00:00 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -1.18 | -1.11 | -4.65 | -2.8 |
| Low Estimate | -1.46 | -1.58 | -6.07 | -3.33 |
| High Estimate | -0.85 | -0.54 | -3.4 | -2.04 |
| Year Ago EPS | -6.75 | -4.54 | -12.17 | -4.65 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -4.12 | -7.12 | -2.36 | -0.95 |
| EPS Actual | -6.75 | -4.54 | -- | -1.37 |
| Difference | -2.63 | 2.59 | -- | -0.42 |
| Surprise % | -63.64% | 36.28% | -- | -44.21% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.18 | -1.11 | -4.65 | -2.8 |
| 7 Days Ago | -1.29 | -1.2 | -4.93 | -2.74 |
| 30 Days Ago | -1.11 | -0.86 | -3.6 | -2.25 |
| 60 Days Ago | -1.11 | -0.86 | -3.6 | -2.25 |
| 90 Days Ago | -1.23 | -0.52 | -3.56 | -2.57 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | -- |
| Up Last 30 Days | 1 | -- | -- | -- |
| Down Last 7 Days | 2 | 2 | 3 | 2 |
| Down Last 30 Days | 2 | 2 | 3 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| FBRX | 82.52% | 75.55% | 61.77% | 39.76% |
| S&P 500 | 13.13% | 2.46% | 7.55% | 14.08% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 4/1/2025 |
| Initiated | TD Cowen: Buy | 1/21/2025 |
| Maintains | Chardan Capital: Buy to Buy | 12/4/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/15/2024 |
| Maintains | Chardan Capital: Buy to Buy | 8/19/2024 |
| Initiated | Brookline Capital: Buy | 5/30/2024 |
Related Tickers
COYA Coya Therapeutics, Inc.
5.88
+3.16%
LSTA Lisata Therapeutics, Inc.
2.6900
+0.37%
KALA KALA BIO, Inc.
4.1400
-0.72%
CMMB Chemomab Therapeutics Ltd.
1.3216
+0.12%
SYRE Spyre Therapeutics, Inc.
16.97
+2.11%
JSPR Jasper Therapeutics, Inc.
6.01
+5.44%
NERV Minerva Neurosciences, Inc.
1.8400
+2.79%
SER Serina Therapeutics, Inc.
5.95
0.00%
SYBX Synlogic, Inc.
1.2112
-0.72%
AKTX Akari Therapeutics, Plc
1.2320
-3.90%